Agendia partners with Cryogene and Mist to distribute breast cancer recurrence assay in the Middle East

Agendia signs partnership agreement with Cryogene and Mist for Middle East distribution

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today a partnership agreement to distribute the company’s breast cancer recurrence assay, MammaPrint^®, in the Middle East. Agendia has signed the distribution partnership agreement with Cryogene S.A.R.L., a healthcare and diagnostics business company specializing in Personalized Medicine Oncology, and its sister company Mist S.A.L.

MammaPrint is a 70-gene breast cancer recurrence assay that predicts the clinical outcome for women with early-stage breast cancer, identifying patients who can safely forego chemotherapy post-surgery and thereby sparing them from unnecessary side effects and toxicity. Currently, MammaPrint is the only FDA-cleared breast cancer prognostic test with the highest level of evidence (1A) for its clinical utility to aid correct identification of low risk patients, as demonstrated by the primary outcome of the MINDACT clinical trial. MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy) results were published in the prestigious peer-reviewed New England Journal of Medicine (NEJM) in August 2016.

Dr. Marjolaine Baldo, Agendia’s EMEA Commercial Vice President said:

With MammaPrint^® giving physicians a proven prognostic test to identify early-stage breast cancer patients who can safely forego chemotherapy, it is important to broaden access to the test to patients worldwide. Our partnership with Cryogene and Mist is an important milestone in making our validated breast cancer recurrence assay available to the medical community in the Middle East.

Dr Rony El Khoury, Cryogene’s CEO commented:

MammaPrint^® has the potential to revolutionize the way that we treat breast cancer patients in the Middle East by providing crucial additional information to enable our doctors to coordinate individual treatment plans. This agreement will assist us in providing doctors and patients with a prognostic test that they can trust, which should rapidly bring benefits to patients, doctors and local healthcare systems.

MammaPrint is the fastest growing breast cancer recurrence assay and has already helped over 48,000 patients from approximately 50 countries around the world. First launched in 2004 in Europe, MammaPrint is now one of the only diagnostic genomic assays with both a CE mark and FDA clearance. MammaPrint will now be available in the Middle East with all patient tumor biopsy samples being analyzed in Agendia’s fully accredited Diagnostics Laboratory in The Netherlands.

Source: http://www.agendia.com/